122 related articles for article (PubMed ID: 9257767)
1. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
[TBL] [Abstract][Full Text] [Related]
2. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
Zhu ZY; Li RC
J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
[TBL] [Abstract][Full Text] [Related]
3. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
Li RC; Zhu ZY
J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.
Zhanel GG; Karlowsky JA; Hoban DJ; Davidson RJ
Chemotherapy; 1991; 37(2):114-21. PubMed ID: 1903340
[TBL] [Abstract][Full Text] [Related]
5. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
[TBL] [Abstract][Full Text] [Related]
6. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.
den Hollander JG; Fuursted K; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1998 Apr; 42(4):749-54. PubMed ID: 9559777
[TBL] [Abstract][Full Text] [Related]
7. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
Majtán V; Hostacká A
Folia Microbiol (Praha); 1996; 41(3):228-32. PubMed ID: 9449771
[TBL] [Abstract][Full Text] [Related]
8. Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.
Wood PJ; Ioannides-Demos LL; Bastone EB; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1996 May; 40(5):1321-4. PubMed ID: 8723496
[TBL] [Abstract][Full Text] [Related]
9. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
[TBL] [Abstract][Full Text] [Related]
10. The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa.
Hybenová D; Majtán V
Pharmazie; 1997 Feb; 52(2):157-9. PubMed ID: 9122276
[TBL] [Abstract][Full Text] [Related]
11. Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity.
Hostacká A
Folia Microbiol (Praha); 1996; 41(1):39-42. PubMed ID: 9090822
[TBL] [Abstract][Full Text] [Related]
12. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa.
Ozbek B; Otuk G
Chemotherapy; 2009; 55(6):446-50. PubMed ID: 19996590
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
14. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
15. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
Canis F; Cavallo JD; Husson MO
Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
[TBL] [Abstract][Full Text] [Related]
18. In vitro postantibiotic effect following repeated exposure to imipenem, temafloxacin, and tobramycin.
McGrath BJ; Marchbanks CR; Gilbert D; Dudley MN
Antimicrob Agents Chemother; 1993 Aug; 37(8):1723-5. PubMed ID: 8215293
[TBL] [Abstract][Full Text] [Related]
19. A study of cefoperazone alone and in combination with tobramycin against Pseudomonas aeruginosa.
Pavillard ER; Miles H
Clin Ther; 1980; 3(Spec Issue):134-8. PubMed ID: 6446387
[TBL] [Abstract][Full Text] [Related]
20. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Field TR; White A; Elborn JS; Tunney MM
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
